HOME >> MEDICINE >> NEWS
OREXIGEN reports positive 24-week results for Contrave phase III obesity treatment study

San Diego, CA, September 26, 2006 -- OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that top line results for the company's lead obesity compound, ContraveTM, demonstrated significant advantages in weight loss in a 24-week multi-center, placebo-controlled phase III trial; the trial will continue unblinded for an additional 24 weeks.

Contrave is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, with one of several different doses of naltrexone, an opioid antagonist used to treat various addictive disorders. The bupropion/naltrexone combination is based on the company's underlying research into the brain's regulation of appetite and energy expenditure, which suggests that combining these two central nervous system drugs may improve the ability to initiate weight loss, and importantly, to continue weight loss by blocking the body's attempts to compensate for weight loss during the treatment. The trial is testing three different dosages of naltrexone combined with the same dosage of bupropion. In what may become the preferred dose pairing based on performance and tolerability, patients completing the 24-week trial using Contrave experienced on average an excess of 7% weight loss from baseline compared to approximately 1% weight loss from baseline on average for patients using the placebo. In addition, the Contrave combination outperformed either naltrexone or bupropion given alone, and the Contrave-associated weight loss trajectory showed no indication of reaching a plateau at the conclusion of 24 weeks of blinded therapy. These findings for Contrave are consistent with an earlier phase II proof of concept study presented at the annual meeting of the American Diabetes Association in June.

"These clinical findings are indicative of a therapeutic synergy when combi
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
26-Sep-2006


Page: 1 2 3

Related medicine news :

1. New study reports hotel guests at risk from carbon monoxide poisoning
2. MIT reports key pathway in synaptic plasticity
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. New study reports improved treatment and reduced mortality for patients with heart failure
5. Study reports changing to a low-fat diet can induce stress
6. Arsenic in chicken feed may pose health risks to humans, C&EN reports
7. Tai Chi boosts immunity to shingles virus in older adults, NIH-sponsored study reports
8. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
9. UCLA study reports conflict of interest policies and practices of major journals
10. New study on school bus safety shows injuries well exceed previous reports
11. Drug company reports should be read with caution, warn doctors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A Bible-inspired ... the creation of published author, Bill Miller. Bill Miller has a unique ... than a decade of addiction to prescription drugs. He has a Bachelor ...
(Date:9/20/2017)... ... , ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving ... off work and rolled up their sleeves to help with relief efforts. The team ... the process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the inspirational solutions ... God. “Psalms of Humidity” is the creation of published author, David Waldrop, an imperfect ... are the very same things that have shaped him into the man that he ...
(Date:9/20/2017)... ... 20, 2017 , ... “The Financial Favor of God; Second Edition”: a personal ... Edition” is the creation of published author, Brooks Rathell. , “We typically hear about ... you about the financial favor of God. Not only does it exist, but it ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, whose ... creation of published author, Colleen Crispi, has owned four beauty salons and written a ... in real estate and cooking. , “The doctor’s office was only three blocks ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... nearly two decades, New Life Agency has been committed to providing the ... Life Agency announces a powerful three-way partnership designed to deliver substantial savings ... ... http://www.schrafts2.com/ (PRNewsfoto/PharmaCareCard) ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology:
Cached News: